Ultra High-Risk Multiple Myeloma Patients with Multi-Hit Tumours and SKY92 High Risk Signature Are at Increased Risk of Early Relapse Even When Treated with Extended Intensified Induction and Consolidation - Results from the Optimum/Muknine Trial
Martin Kaiser(Royal Marsden NHS Foundation Trust), Matthew Jenner(University Hospital Southampton NHS Foundation Trust), Gordon Cook(University of Leeds), Rachel Phillip(University of Leeds), Laura Clayton(University of Leeds), Mark T. Drayson(Institute of Immunology), Guy Pratt(University Hospitals Birmingham NHS Foundation Trust), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Laura Bevington(Institute of Cancer Research), Sarah Brown(University of Leeds), Sadie Roberts(University of Leeds), Andrew Hall(University of Leeds), Graham Jackson(Newcastle College), Ruth M. de Tute(St James's University Hospital), Amy Holroyd(Institute of Cancer Research), Richard S. Houlston(Institute of Cancer Research)
Cited by 8
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Genome-wide association study identifies five susceptibility loci for glioma
|Nature Genetics|2009|797
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial
|The Lancet|2010|640
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2008|605